Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

University of Science and Technology of China (USTC)

Status: Enrolling

Conditions: Cytomegalovirus Infection Reactivation

Treatments: Drug: Letermovir

Study type: Observational

Funder types: Other

Identifiers

NCT06441669

CBCMV001

Details and patient eligibility

About

To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation

Full description

To explore the effect of letermovir prophylaxis on cytomegalovirus-specific and other lymphocyte subsets immune reconstitution post unrelated cord blood transplantation, and to analyze the potential mechanism and risk factors of late CMV reactivation after letermovir discontinuation.

Enrollment: 60 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients are receiving a first unrelated cord blood transplantation (UCBT).
• Patients start letemovir prophylaxis within 0-28 days post UCBT.

Exclusion criteria

• Patients having active CMV DNAemia at the time of letermovir initiation.
• Patients recruited in a clinical study on an anti-CMV trial.

Trial design

60 participants in 1 patient group

letermovir group

Description:

Patients will be given Letermovir with a recommended dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine or according to clinical instructions) from +1 day to +100 days after UCBT.

Treatment:

Drug: Letermovir